News & Events
March 18, 2020
C-Path and Lundbeck Announce a Data Sharing Collaboration to Enable Development of Advanced Drug Development Tools in Alzheimer’s Disease
C-Path and H. Lundbeck A/S are proud to announce that they will work together to significantly improve the scientific community’s insight in Alzheimer’s disease through Lundbeck’s contribution of a unique set of clinical trial data from more than 2,500 AD patients to the Critical Path for Alzheimer’s Disease consortium’s integrated database for qualified researchers across the globe to access.
March 12, 2020
C-Path Selects Experienced Neuroscientist to Lead Alzheimer’s Consortium
The Critical Path Institute (C-Path) today announced it has named Sudhir Sivakumaran, Ph.D., as Executive Director of its Critical Path for Alzheimer’s Disease (CPAD) consortium effective immediately. Dr. Sivakumaran, a neuroscientist and research and development professional, has nearly 20 years combined experience in academic, pre-clinical and early clinical research and development, phase 1 and phase 2 clinical study design, data analysis and diligence and business development. He has been with C-Path since July 2019 as Associate Director for CPAD.
November 5, 2018
Critical Path Institute Rebrands One of Its First Consortia to Highlight Focus on Alzheimer’s DiseaseCritical Path for Alzheimer’s Disease (CPAD) consortium’s refined, refocused mission centers on accelerating therapy development for AD and related forms of dementia TUCSON, Ariz., November 5, 2018 — The Critical Path Institute (C-Path) is pleased to announce that its Critical Path for Alzheimer’s Disease (CPAD) consortium has refined and refocused its mission in celebration of......
May 2, 2016
Coalition Against Major Diseases (CAMD) Becomes a Partner in Massive Global Alzheimer’s Research Data-Sharing NetworkMay 2, 2016 Coalition Against Major Diseases (CAMD) Becomes a Partner in Massive Global Alzheimer’s Research Data-Sharing Network TUCSON, Ariz. — May 2, 2016 — The Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD) is announcing it will integrate its Alzheimer’s clinical trial data into the Global Alzheimer’s Association Interactive Network (GAAIN)......
April 27, 2015
Critical Path Institute Secures Regulatory Support For Parkinson’s And Alzheimer’s Disease BiomarkersApril 27, 2015 Critical Path Institute Secures Regulatory Support For Parkinson’s And Alzheimer’s Disease Biomarkers FDA Endorses Biomarkers for Use in Early Stages of Brain Disease TUCSON, Ariz., April 27, 2015 — Critical Path Institute (C-Path) announced that the U.S. Food and Drug Administration (FDA) has issued three Letters of Support to C-Path’s Coalition Against......